NASDAQ:OVID Ovid Therapeutics (OVID) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free OVID Stock Alerts $3.10 -0.05 (-1.59%) (As of 11:45 AM ET) Add Compare Share Share Today's Range$3.04▼$3.1450-Day Range$2.72▼$3.8452-Week Range$2.57▼$4.14Volume28,279 shsAverage Volume193,070 shsMarket Capitalization$219.20 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Ovid Therapeutics alerts: Email Address Ovid Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside190.3% Upside$9.00 Price TargetShort InterestBearish4.78% of Float Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$50,364 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.65) to ($0.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.16 out of 5 starsMedical Sector97th out of 907 stocksPharmaceutical Preparations Industry32nd out of 422 stocks 3.5 Analyst's Opinion Consensus RatingOvid Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOvid Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.78% of the float of Ovid Therapeutics has been sold short.Short Interest Ratio / Days to CoverOvid Therapeutics has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldOvid Therapeutics does not currently pay a dividend.Dividend GrowthOvid Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOvid Therapeutics has received a 71.15% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for Epilepsy or seizures" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Ovid Therapeutics is -0.85. Previous Next 1.9 News and Social Media Coverage News SentimentOvid Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.MarketBeat Follows4 people have added Ovid Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ovid Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,364.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.60% of the stock of Ovid Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.24% of the stock of Ovid Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ovid Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ovid Therapeutics is -4.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ovid Therapeutics is -4.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOvid Therapeutics has a P/B Ratio of 2.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchSee this before next week's Fed meetingSee this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) Click here to see it. About Ovid Therapeutics Stock (NASDAQ:OVID)Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Read More OVID Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OVID Stock News HeadlinesApril 18, 2024 | finance.yahoo.comWe Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business GrowthApril 5, 2024 | msn.comOvid Therapeutics gains on bullish view at WedbushApril 25, 2024 | Chaikin Analytics (Ad)“The Biggest Bubble of All Time” – Here’s What to Do.Despite AI's incredible run-up in 2023, we're getting some conflicting messages. Analysts at JP Morgan warn that an "AI-driven bubble" could drag the entire stock market down. Folks at Morgan Stanley say AI hysteria is creating conditions like the dot-com collapse. Even AI leaders (the people who benefit the most!) are getting worried.April 4, 2024 | globenewswire.comOvid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceApril 2, 2024 | msn.comMarinus Pharmaceuticals Stands Firm in Patent Dispute Over Key Epilepsy TreatmentMarch 29, 2024 | bizjournals.comMarinus Pharmaceuticals' patent battle with New York firm over seizure therapy takes new twistMarch 22, 2024 | investing.comOvid therapeutics CEO acquires $50k in company stockMarch 22, 2024 | finance.yahoo.comOvid Therapeutics Reaches US$197m Market Cap Benefiting Insider Stock BuyingApril 25, 2024 | Chaikin Analytics (Ad)“The Biggest Bubble of All Time” – Here’s What to Do.Despite AI's incredible run-up in 2023, we're getting some conflicting messages. Analysts at JP Morgan warn that an "AI-driven bubble" could drag the entire stock market down. Folks at Morgan Stanley say AI hysteria is creating conditions like the dot-com collapse. Even AI leaders (the people who benefit the most!) are getting worried.March 17, 2024 | insidermonkey.com5 Oversold Biotech Stocks To Buy Right NowMarch 13, 2024 | markets.businessinsider.comOvid Therapeutics: Strong Buy Rating on Robust Pipeline and Strategic PartnershipsMarch 13, 2024 | news.yahoo.comOvid gas station, state and local officials dealing with contaminated fuel problemMarch 13, 2024 | msn.comOvid gas station shut down after discovery of water inside pumpsMarch 11, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Ovid Therapeutics (OVID)March 9, 2024 | finance.yahoo.comOVID Oct 2024 7.500 callMarch 8, 2024 | benzinga.comRecap: Ovid Therapeutics Q4 EarningsMarch 8, 2024 | globenewswire.comOvid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | investing.comOvid Therapeutics Inc (OVID)February 28, 2024 | globenewswire.comOvid Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 22, 2024 | news.yahoo.comOvid-Elsie girls win third straight conference titleFebruary 17, 2024 | finance.yahoo.comOVID Mar 2024 5.000 callFebruary 17, 2024 | finance.yahoo.comOVID Apr 2024 5.000 callFebruary 15, 2024 | msn.comTaysha transfers rights to 3 programs, extends cash runway into 2026February 6, 2024 | finance.yahoo.comOvid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 1, 2024 | msn.comCirculatory cholesterol levels are inversely linked to mortality of patients with sepsis and critical illnessJanuary 18, 2024 | finance.yahoo.comOwning 31% shares,hedge funds owners seem interested in Ovid Therapeutics Inc. (NASDAQ:OVID),January 3, 2024 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Ovid Therapeutics (OVID)See More Headlines Receive OVID Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/08/2024Today4/25/2024Next Earnings (Estimated)5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OVID CUSIPN/A CIK1636651 Webwww.ovidrx.com Phone(646) 661-7661FaxN/AEmployees40Year Founded2014Price Target and Rating Average Stock Price Target$9.00 High Stock Price Target$11.00 Low Stock Price Target$8.00 Potential Upside/Downside+185.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,340,000.00 Net Margins-13,351.53% Pretax Margin-13,351.79% Return on Equity-49.76% Return on Assets-38.16% Debt Debt-to-Equity Ratio0.17 Current Ratio9.55 Quick Ratio9.55 Sales & Book Value Annual Sales$390,000.00 Price / Sales571.12 Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book2.54Miscellaneous Outstanding Shares70,710,000Free Float61,801,000Market Cap$222.74 million OptionableOptionable Beta0.71 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Jeremy Max Levin Ba Zoology (Age 71)Dphil, Mb Bchir, President, CEO & Chairman Comp: $923.54kMr. Jeffrey A. Rona (Age 56)Principal Financial Officer, Principal Accounting Officer & Chief Business and Financial Officer Comp: $686.28kMr. Jason Tardio M.B.A. (Age 46)Chief Operating Officer Comp: $652.84kMs. Lora PikeSenior Director of Investor Relations & Public RelationsMr. Thomas Michael Perone J.D. (Age 58)M.B.A., General Counsel Comp: $632.11kMr. Simon D. Kelner (Age 50)Chief Human Resources Officer Dr. Dirk Haasner (Age 59)Senior Vice President of Global Manufacturing & CMC QA Comp: $416.95kDr. Todd F. Baumgartner M.D.M.P.H., Senior Vice President of Regulatory AffairsDr. Julia Tsai Ph.D. (Age 49)Senior Vice President of Clinical Development Ms. Meg AlexanderChief Strategy OfficerMore ExecutivesKey CompetitorsuniQureNASDAQ:QUREConduit PharmaceuticalsNASDAQ:CDTAcrivon TherapeuticsNASDAQ:ACRVAldeyra TherapeuticsNASDAQ:ALDXImmutepNASDAQ:IMMPView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 35,786 shares on 4/24/2024Ownership: 0.162%Jeremy M LevinBought 18,248 shares on 3/18/2024Total: $50,364.48 ($2.76/share)Rubric Capital Management LPSold 129,941 shares on 2/14/2024Ownership: 7.521%Vestal Point Capital LPBought 85,429 shares on 2/14/2024Ownership: 0.121%DCF Advisers LLCSold 11,700 shares on 2/13/2024Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions OVID Stock Analysis - Frequently Asked Questions Should I buy or sell Ovid Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OVID shares. View OVID analyst ratings or view top-rated stocks. What is Ovid Therapeutics' stock price target for 2024? 3 Wall Street research analysts have issued twelve-month target prices for Ovid Therapeutics' stock. Their OVID share price targets range from $8.00 to $11.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 190.3% from the stock's current price. View analysts price targets for OVID or view top-rated stocks among Wall Street analysts. How have OVID shares performed in 2024? Ovid Therapeutics' stock was trading at $3.22 at the start of the year. Since then, OVID stock has decreased by 3.7% and is now trading at $3.10. View the best growth stocks for 2024 here. Are investors shorting Ovid Therapeutics? Ovid Therapeutics saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 2,800,000 shares, a decline of 23.7% from the March 15th total of 3,670,000 shares. Based on an average daily trading volume, of 205,000 shares, the days-to-cover ratio is currently 13.7 days. Currently, 4.8% of the company's stock are short sold. View Ovid Therapeutics' Short Interest. When is Ovid Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our OVID earnings forecast. How were Ovid Therapeutics' earnings last quarter? Ovid Therapeutics Inc. (NASDAQ:OVID) posted its quarterly earnings results on Friday, March, 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.05. The company earned $0.14 million during the quarter, compared to analysts' expectations of $0.10 million. Ovid Therapeutics had a negative trailing twelve-month return on equity of 49.76% and a negative net margin of 13,351.53%. What other stocks do shareholders of Ovid Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Enphase Energy (ENPH), Gilead Sciences (GILD) and Novavax (NVAX). When did Ovid Therapeutics IPO? Ovid Therapeutics (OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers. Who are Ovid Therapeutics' major shareholders? Ovid Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.16%). Insiders that own company stock include Amit Rakhit, Jason Tardio and Jeremy M Levin. View institutional ownership trends. How do I buy shares of Ovid Therapeutics? Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OVID) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsPrepare for a recession unlike any otherAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
